SS Innovations Reiterates Guidance for First Quarter 2025 and Provides Commentary on Second Quarter 2025 Order Trends

Rhea-AI Summary

SS Innovations (NASDAQ: SSII) has reiterated its Q1 2025 guidance and provided Q2 2025 order trends. The company installed 14 SSi Mantra surgical robotic systems in Q1 2025, bringing the total installed base to 78 systems as of March 31, 2025. Expected Q1 2025 revenue is approximately $6.4 million with a 45% gross margin. As of April 30, 2025, the installed base reached 80 systems across 75 hospitals, with over 3,800 surgeries completed, including more than 200 robotic cardiac surgeries. System orders in April 2025 totaled 9 units, representing a 200% increase from April 2024. The company plans to report Q1 2025 financial results around May 15, 2025.

Positive

• 200% year-over-year increase in April orders (9 vs 3)
• Strong Q1 2025 gross margin of 45%
• 14 new system installations in Q1 2025
• Growing installed base reaching 80 systems
• Over 3,800 successful surgeries completed, including 200+ cardiac procedures

Negative

• Relatively modest quarterly revenue of $6.4 million despite system installations
• Financial results are preliminary and subject to change

FORT LAUDERDALE, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today reiterated guidance for the first quarter of 2025.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “Following our recent uplisting to Nasdaq, we remain very pleased with the growth trajectory of our business as we conclude the first quarter of 2025 and enter the second quarter. We believe that we are well-positioned to maintain this momentum and achieve new and impactful milestones throughout 2025.”

The Company reiterated:

• 14 SSi Mantra surgical robotic systems were installed during the first quarter of 2025, bringing the cumulative installed base to 78 as of March 31, 2025.
• Revenue for the first quarter of 2025 is expected to be approximately $6.4 million with a gross margin of approximately 45%, based on preliminary unaudited results which are subject to change.

The Company also provided the following updates:

• As of April 30, 2025, 80 SSi Mantra robotic surgical systems have been installed in 75 hospitals and more than 3800 surgeries have utilized the SSi Mantra, including over 200 robotic cardiac surgeries.
• SSi Mantra robotic surgical system orders totaled 9 in the first month of the second quarter, April 2025, up 200% from 3 orders in April 2024.

The Company anticipates reporting first quarter 2025 financial results on or about May 15, 2025.

About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.

About the SSi Mantra
The SSi Mantra Surgical Robotic System is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.

Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations International’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Investor Contact:
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
kahl@equityny.com

Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@equityny.com

Media Contact:
press@ssinnovations.org
T: (212) 739-0300

FAQ

What is SSII's expected revenue for Q1 2025?

SS Innovations (SSII) expects Q1 2025 revenue of approximately $6.4 million with a gross margin of 45%, based on preliminary unaudited results.

How many SSi Mantra surgical systems did SSII install in Q1 2025?

SSII installed 14 SSi Mantra surgical robotic systems during Q1 2025, bringing their total installed base to 78 systems as of March 31, 2025.

What is the growth rate of SSII's system orders in April 2025?

SSII reported a 200% year-over-year growth in system orders, with 9 orders in April 2025 compared to 3 orders in April 2024.

How many surgeries have been performed using SSII's SSi Mantra system?

As of April 30, 2025, over 3,800 surgeries have been performed using the SSi Mantra system, including more than 200 robotic cardiac surgeries.

When will SSII report its Q1 2025 financial results?

SS Innovations plans to report its Q1 2025 financial results on or about May 15, 2025.